Multinational pharmaceutical company preparing to enter the
Oncology Market.
A multinational pharmaceutical company with a
robust pipeline of oncology therapies was seeking product development,
clinical development, and market development for its lead oncology
compound. The product had met Phase I requirements and was moving
into Phase II. It would be the second market entry in the class
and would be competing against a well established brand. Given
this situation, the company needed to prioritize potential indications
and find the optimal route for clearing FDA registration hurdles.
To facilitate successful clinical development,
launch, and market penetration of the lead oncology compound.
Because of the uncertainty of clinical development,
we conducted an evaluation of existing and prospective diagnostic
and treatment pathways. This approach
allowed us to determine future unmet needs and patient accrual
across multiple indications. ISA’s scientific experts created
a Claims Map that defined the variables affecting approval of
future indications and the resulting regulatory and competitive
positioning across multiple market scenarios. These scenarios
helped us formulate a set of commercial priorities and action
plans.
Senior leadership of the company’s Oncology
therapeutic area reviewed the Claims Map with ISA’s project
team. Based upon that evaluation, the company restructured its
allocation of resources for its entire oncology portfolio. This
included re-sizing the sales force and restructuring the organization's
commercial and clinical teams. ISA’s risk-adjusted view
of the market environment helped the client better define a
funding request from global senior management. This assessment
focused on the product’s best chance for a favorable development
outcome and balanced that against the need for a positive return-on-investment.
){kind=link}
){kind=link}
){kind=link}